Vcanbio Cell & Gene Engineering Corp Stock

Vcanbio Cell & Gene Engineering Corp Liabilities

The The Liabilities of Vcanbio Cell & Gene Engineering Corp (600645.SS) as of Aug 5, 2026 is 1.65 B CNY. In the previous year, The Liabilities was 1.73 B CNY — a change of -4.25% (lower).

Liabilities

1.65 BCNY

YoY

-4.25%

Last updated:

In 2026, Vcanbio Cell & Gene Engineering Corp's total liabilities amounted to 1.65 B CNY, a -4.25% difference from the 1.73 B CNY total liabilities in the previous year.

Access this data via the Eulerpool API
Get Free API Key

Vcanbio Cell & Gene Engineering Corp Stock analysis

What does Vcanbio Cell & Gene Engineering Corp do? Vcanbio Cell & Gene Engineering Corp is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Vcanbio Cell & Gene Engineering Corp's Liabilities

Vcanbio Cell & Gene Engineering Corp's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Vcanbio Cell & Gene Engineering Corp's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Vcanbio Cell & Gene Engineering Corp's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Vcanbio Cell & Gene Engineering Corp's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Vcanbio Cell & Gene Engineering Corp’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Vcanbio Cell & Gene Engineering Corp stock

The Liabilities of Vcanbio Cell & Gene Engineering Corp is 1.65 B CNY in 2026.

The Liabilities of Vcanbio Cell & Gene Engineering Corp changed from 1.73 B CNY to 1.65 B CNY, representing a -4.25% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Vcanbio Cell & Gene Engineering Corp since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Vcanbio Cell & Gene Engineering Corp historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — Vcanbio Cell & Gene Engineering Corp

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Vcanbio Cell & Gene Engineering Corp